SLC5A2 and diabetes mellitus: Glucagon like peptide 1-receptor agonists (GLP-1) and sodium glucose co-transporter 2 inhibitors (SGLT2) may improve cardiovascular outcome, in patients with diabetes mellitus and cardiovascular disease.